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Numerous studies by our lab and others demonstrate that epidermal growth factor receptor (EGFR) plays critical
roles in primary breast cancer (BC) initiation, growth and dissemination. However, clinical trials targeting EGFR
function in BC have lead to disappointing results. In the current study we sought to identify the mechanisms
responsible for this disparity by investigating the function of EGFR across the continuum of the metastatic
cascade. We previously established that overexpression of EGFR is sufficient for formation of in situ primary
tumors by otherwise nontransformed murine mammary gland cells. Induction of epithelial-mesenchymal transition
(EMT) is sufficient to drive the metastasis of these EGFR-transformed tumors. Examining growth factor receptor
expression across this and other models revealed a potent downregulation of EGFR through metastatic
progression. Consistent with diminution of EGFR following EMT and metastasis EGF stimulation changes from a
proliferative to an apoptotic response in in situ versus metastatic tumor cells, respectively. Furthermore,
overexpression of EGFR in metastatic MDA-MB-231 BC cells promoted their antitumorigenic response to EGF in
three dimensional (3D) metastatic outgrowth assays. In line with the paradoxical function of EGFR through EMT
and metastasis we demonstrate that the EGFR inhibitory molecule, Mitogen Induced Gene-6 (Mig6), is tumor
suppressive in in situ tumor cells. However, Mig6 expression is absolutely required for prevention of apoptosis and
ultimate metastasis of MDA-MB-231 cells. Further understanding of the paradoxical function of EGFR between
primary and metastatic tumors will be essential for application of its targeted molecular therapies in BC.
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Epidermal growth factor receptor (EGFR) is a well-established
proto-oncogene. Indeed, we demonstrated that the overexpression of
EGFR is capable of transforming mammary epithelial cells, and that
transforming growth factor β (TGF-β)–mediated epithelial-mesenchymal
transition (EMT) in concert with EGFR facilitates primary mammary
tumor cell invasion and dissemination [1,2]. Along these lines, primary
breast tumors expressing elevated levels of EGFR display decreased
clinical prognosis [3]. These and other findings point to the targeting of
EGFR as an effective means by which to combat breast cancer (BC)
metastasis. However, the clinical application of EGFR-targeting agents to
treat BC has been largely unsuccessful [4–6]. The molecular mechanisms
that underlie this inherent resistance of BC to EGFR-targeted therapies
remain undefined.
An emerging topic in the field of EGFR signaling is the role of
inhibitory proteins that function to mitigate signaling following EGFR
activation. One such protein is Mitogen Inducible Gene-6 (Mig6), also
known as receptor-associated late transducer (RALT), Gene33, or ErbB
receptor feedback inhibitor (ERRFI). Cells utilize Mig6 and other
feedback inhibitory molecules to balance physiological signaling
emanating from EGFR in terms of both time and intensity [7].
Mechanistically,Mig6 binds to the intracellular domain of EGFR via its
EGFR binding Region (EBR) and inhibits downstream signaling to
various effector molecules such as Erk1/2 and Akt [8,9]. Furthermore,
Mig6 is genetically altered and transcriptionally silenced in lung cancer,
a cancer that can be driven by constitutive activation of EGFR [9].
Genetic deletion of Mig6 results in tumor formation in mice due to
hyper-activation of EGFR [10]. Finally, in addition to EGFR,Mig6 has
more recently been shown to bind to and facilitate c-Abl nuclear
translocation leading to induction of apoptosis [11].
While the studies referenced above point to Mig6 as a growth
inhibitory, pro-apoptotic and overall tumor suppressive molecule,
contrasting studies have demonstrated its function in tumor progression
and inhibition of apoptosis. For instance, several breast cancer cell lines
express high levels of Mig6 and overexpression of Mig6 in MCF-7 BC
cells inhibits thier apoptosis [12]. Similarly, while genetic depletion of
Mig6 does lead to hyperplasia in several organs it is also associated with
enhanced apoptosis in endothelial cells [13]. Correspondingly,
depletion of the Mig6 in bronchiolar epithelial cells does lead to
increased cell proliferation, but similar measures in endothelial cells
leads to apoptosis [13]. Along these lines, EGF stimulation can induce
apoptosis in EGFR-amplified BC cells [14–17].We recently established
that EGFR expression is diminished in fully metastatic BC cells as
compared to their systemically invasive but dormant counterparts, and
loss of high level EGFR expression can be brought about during
recovery from TGF-β–induced epithelial-mesenchymal transition
(EMT) [18]. Thus, the precise role of Mig6 and its regulation of pro
versus antitumorigenic EGFR signaling during BC metastasis remain
incompletely understood.
In the current study we delineate a paradoxical shift in EGFR
function through the metastatic progression of BC. Using recombinant
gene overexpression we clearly demonstrate that Mig6 acts as a tumor
suppressor in EGFR-driven in situ mammary tumors. In contrast,
interrogating several models of metastatic progression and clinical
datasets uniformly indicate that as BCs progress from in situ to
metastatic disease, EGFR expression is diminished. Consistent with an
antitumorigenic function of EGFR during late-stage metastatic
progression, overexpression of EGFR or depletion of Mig6 in
MDA-MB-231 cells promoted their apoptosis and dramaticallyreduced their outgrowth in 3D culture and formation of pulmonary
tumors in mice. Collectively, our data delineate a paradoxical shift in
EGFR function through the metastatic progression of BC. These
findings demonstrate a plausible mechanism to explain the inherent
resistance of metastatic BC to EGFR-targeted therapies.
Materials and Methods
Cell lines and Cell Culture
Murine NMuMG, human MDA-MB-231, and human
MDA-MB-468 cells were purchased from ATCC and cultured as
described previously [2,19]. Construction of NMuMG cells expressing
human wild type (WT)-EGFR (NME) and their metastatic variants are
described elsewhere [1,2]. Cellular depletion ofMig6 inMDA-MB-231
was accomplished by VSVG lentiviral transduction of pLKO.1 shRNA
vectors as previously described (Thermo Scientific), sequences of
shRNAs can be found in Supplementary Table 1 [2]. The human
MCF10A parental cell line and its increasingly tumorigenic variants
T1k, Ca1h and Ca1a were kindly provided by Dr. Fred Miller (Wayne
State University) and were cultured as described previously [20]. A list
of the chemical inhibitors used throughout the study can be found in
Supplementary Table 2.
Immunoblotting and Immunofluorescent Analyses
For immunoblot assays, equal aliquots of total cellular protein were
resolved by SDS-PAGE and transferred to PVDF membranes using
standard methods as described [21]. Immunofluorescent assays were
conducted using primary antibodies in combination with a biotinylated
secondary antibodies (Jackson) and Texas-Red conjugated avidin
(Vector) as described [1]. Antibody concentrations and suppliers are
listed in Supplementary Table 3.
Cell Biological Assays
DNA synthesis was measured by [3H]thymidine incorporation as
previously described [18]. Caspase 3/7 activity was quantified using the
Caspase 3/7 Glo reagent (Promega) according to the manufacturer’s
instructions. Visualization of the actin cytoskeleton was perform by
staining fixed cells with FITC-conjugated Phalloidin according to the
manufactures instructions (Thermo Scientific).
Three-Dimensional (3D) Organotypic Growth Assays
Ninety-six well plates were coated with Cultrex (50 μl/well) and cells
were resuspended in DMEM supplemented with 10% FBS and 4%
Cultrex (150 μl/well). Luciferase-expressing cells were seeded at a
density of 1 × 103 cells/well. Media containing the indicated inhibitors
or growth factors was replaced every 4 days and organoid outgrowth was
detected by the addition of D-luciferin potassium salt (Gold
Biotechnology) to induce bioluminescence, which was quantified
using a GloMax-Multi detection system (Promega).
Tumor Growth and Metastasis Analysis
Orthotopic NME tumors were established and tumor volume was
quantified as previously described [2]. Pulmonary tumor development
was assessed by injection of parental (scrambled shRNA) and
Mig6-deficient cells into the lateral tail vein of nu/nu mice (1 × 106
cells/mouse). Where indicated tumor growth and metastasis was
monitored by in vivo bioluminescent imaging as previously described
[1,2,18,20,22]. Bioluminescent images were captured on a Xenogen
IVIS-200 (PerkinElmer). All animal procedures were performed in
accordance to protocols approved by the Institutional Animal Care and
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In Silico Analyses
The Cancer Cell Line Encyclopedia contains a repository of log2
expression data derived from Affymetrix U133+2.0 Arrays for 947
unique human cancer cell lines. GEO Dataset GSE3744 contains
expression data using the Affymetrix U133+2.0 for clinical samples
classified as basal-like and non-basal-like [23]. This dataset was analyzed
using the NCBI curated dataset browser tool. The TCGA [24] dataset
was accessed via cBioPortal and analyzed using R.
Statistical Analyses
Statistical analyses were carried out using an unpaired Student’s
T-test. P values b 0.05 were considered statistically significant. P values
for all experiments are indicated. Correlation coefficients and P values
were generated using Prizm-Graph Pad.Figure 1. Recombinant expression of Mig6 is capable of reversing E
express Myc-tagged WT or the EGFR binding region (EBR) of Mig6. Ex
by immunoblot (EBR lacks the epitope of the Mig6 antibody), Myc
assessed as a positive control. (B) Control (GFP) and Mig6 expressin
(arrows denoted filopodia) and within 3D organotypic culture conditi
cell structures as shown in panel B were quantified for control and M
hollow versus filled structures per 10 high powered fields where ** ind
Mig6 expressing NME cells were stimulated with the indicated conce
by immunoblot for phosphorylation of EGFR (pEGFR) and Stat3 (pSta
Stat3 (tStat3) and Myc as loading controls. Data in panels A and D a
expressing GFP as a control (GFP) or Mig6-EBR (EBR) were engrafte
tumor growth was monitored by caliper measurements. * Indicates
and Mig6-EBR (EBR) primary tumor excised from mice 50 days after
panel F, P value is indicated.Results
Mig6 is Tumor Suppressive in an EGFR-Driven In Situ Model
of Breast Cancer
Mig6 has previously been described as a tumor suppressor [10],
findings that are contingent upon EGFR acting as a protumorigenic
molecule. To verify the ability of Mig6 to suppress EGFR-induced
tumorigenesis, we sought to heterologously overexpress Myc-tagged
Mig6 constructs in our in situmodel of normal murinemammary gland
(NMuMG) cells transformed by overexpression of EGFR (referred to
here as NME cells) (Figure 1A). Importantly, expression of these
constructs did not appreciably affect EGFR levels in our recombinant
system (Figure 1A). However, when these cells were cultured on 2D
plastic substrates under a mixture of extracellular matrix, expression of
the EGFR-binding region (EBR) orWTMig6 decreased the formation
of filopodia (arrows), an event we have previously attributed to the
function of EGFR in these cells (Figure 1B; [25]). Furthermore, whenGFR-mediated transformation. (A) NME cells were constructed to
pression of endogenous and recombinant WT-Mig6 were analyzed
and EGFR were also analyzed in these same lysates. Actin was
g cells were cultured on plastic under a cultrex-containing medium
ons. (C) Filled (transformed) versus hollowed (nontransformed) 3D
ig6 expressing NME cells. Data are the mean percentages (±SE) of
icates P b .01 as compared to the GFP control cells. (D) Control and
ntrations of EGF for 30 minutes. Cells were subsequently analyzed
t3). These blots were striped and reprobed for total EGFR (tEGFR),
re representative of at least 3 independent analyses. (E) NME cells
d (2x106 cells per mouse) onto the mammary fatpad of mice and
P b .01, n = 5 mice per group. (F) Visualization of control (GFP)
engraftment. (G) Mean and SE of wet weights of tumors shown in
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EBR and WT Mig6 significantly enhanced the formation of hollow,
acinar structures, characteristic of normal mammary epithelial cells
(Figure 1, B and C). Furthermore, expression of EBR and WT Mig6
decreased the ability of EGF to induce phosphorylation of EGFR at
Y845 (Figure 1D). We recently demonstrated that the ability of EGFR
to transform NMuMG cells is dependent upon downstream activation
of Stat3 [19]. Importantly, this critical signaling event was potently
inhibited by expression of EBR and WT Mig6 (Figure 1D). To focus
specifically on the ability of the EGFR-directed function of Mig6 to
inhibit tumor initiation we engrafted the NME cells expressing GFP or
Mig6-EBR onto the fat pad of mice and primary tumor formation was
monitored by calipermeasurements (Figure 1E).Mig-EBRdramatically
reduced the ability of NME cells to form primary tumors (Figure 1, F
and G). Collectively, these findings indicate that EGFR-initiated
tumorigenesis can be normalized by the inhibitory actions of Mig6.
Metastatic Breast Cancer Cells Become Inherently Resistant to
Targeted Inhibition of EGFR
NME tumors can be driven tometastasize by a transient induction of
EMT via treatment with TGF-β1 prior to allograft onto the mammary
fat pad [2]. Isolation of the resulting pulmonary metastases yielded the
highly aggressive NME-LM cell line. This cell line undergoes robust
primary tumor formation and spontaneous pulmonary metastasis upon
mammary fat pad engraftment, independent of TGF-β pretreatment
[2]. Isolation of these resultant pulmonary metastases yielded the
NME-LM2 cell line. These isogenic cell lines now constitute a
progression series of cells ranging from nontransformed (NMuMG) to
carcinoma in situ (NMuMG cells transformed by EGFR overexpres-
sion, NME) to highly metastatic (NME-LM and NME-LM2) [2].Figure 2. EGFR transformed mammary epithelial cells become inhere
B) NME and NME-LM (1x106) cells were engrafted onto the mamma
treated daily with Erlotinib (50mg/kg). At the indicated time points (line
monitored for recurrent tumors. (C) Bioluminescent images showin
tumors described in panels A and B to systemic Erlotinib treatment
control and Erlotinib-treated mice. (F) Pulmonary dissemination of NM
by bioluminescence at the indicated time points following fat pad engr
4 mice per group) where * indicates P b .05. (G) Representative ex viv
lungs from control and Erlotinib-treated NME-LM tumor bearing micGiven the ability of Mig6-EBR to prevent NME tumor formation we
next sought to verify inhibition of primary tumor development via
pharmacological inhibition of EGFR. Indeed, similar to expression of
Mig6-EBR, daily oral administration of Erlotinib (50 mg/kg) to mice
bearing orthotopic NME cell engraftments dramatically reduced tumor
formation (Figure 2, A, C and D). In line with our previous report, no
tumor recurrence or metastases were observed by these cells irrespective
of EGFR-directed therapy (Figure 2A; [2]). In stark contrast to the
NME cells, tumor formation by the NME-LM cells (described above)
was only minimally delayed by Erlotinib treatment (Figure 2B), and no
significant differences were observed in primary tumor weight at the
time of primary tumor excision (Figure 2E). Also, following primary
tumor excision, NME-LM tumor recurrence was actually enhanced by
Erlotinib treatment (Figure 2B). Consistent with the role of EGFR in
primary tumor cell dissemination [1,26], pulmonary dissemination of
NME-LM cells was delayed by Erlotinib (Figure 2F), but at the time of
necropsy robust pulmonary metastases were observed in NME-LM
tumor bearing mice irrespective of treatment (Figure 2G). Taken
together, these data strongly suggest that through the processes of
EMT and metastasis even BC cells whose initial transformation is
driven by EGFR are capable of inherently developing resistance to
EGFR-targeted therapy.
EGFR Expression is Diminished Following EMT and Metastasis
Given the inherent resistance of the NME-LM cells to EGFR
targeted therapy, we next sought to utilize this isogenic system to
identify mediators of this process. As noted above, NME cells can be
driven to metastasize via TGF-β–induced EMT prior to tumor cell
engraftment [2]. Our previous in vitro studies demonstrate that EGFR
is not modulated during induction of EMT by TGF-β1, but EGFR isntly resistant to Erlotinib following EMT-induced metastasis. (A and
ry fat pad of female nu/nu mice and 14 days thereafter mice were
on graph), primary tumors were surgically removed andmice were
g the sensitivity (NME) and resistance (NME-LM) of the indicated
. (D) Ex-vivo visualization and (E) weight of indicated tumors from
E-LM tumors in control and Erlotinib-treated mice was determined
aftment. For panel A–B and E–F data are themean values ± SE (n =
o bioluminescence images demonstrating robust metastasis in the
e.
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examine this phenomenon in vivo, we conducted single cell analysis of
cell surface EGFR levels in cells subcultured from control (NS) orFigure 3. EGFR expression is diminished following EMT-induced m
TGF-β1–pretreated (TGF-β) NME primary tumors were disassociate
resultant cultures were analyzed by flow-cytometry for cell surface E
post-EMT tumors by FACS analysis (denoted by the red box) resulted
post-EMT primary tumor cells were co-stained with antibodies again
against EGFR (ii). Arrows denote cells with a highly mesenchymal phe
EGFR. (C) NME-LM cells and their parental NME counterparts were a
NME and NME-LM cells were treated for 48 hours with EGF (50 ng/ml)
were analyzed by immunoblot for cleavage of PARP and expression le
under 3D-culture conditions in the presence of EGF or AG1478 wa
independent experiments completed in triplicate resulting in the indic
hours and subsequently stimulated with the indicated concentratio
phosphorylated EGFR (pEGFR). This blot was striped and reprobed
panels A-D and F are representative of at least two independent expTGF-β1 pretreated NME primary tumors. Figure 3A shows flow
cytometry using an antibody specific for the human EGFR transgene
(Figure 3A). These two ex vivo primary tumors displayed similar EGFRetastasis. (A) Following primary tumor removal, control (NS) and
d and subcultured in the presence of Puromycin (5 μg/ml). The
GFR. Isolation of the distinct EGFR-negative population within the
in a highly mesenchymal cell population. (B) Ex-vivo subcultured,
st Ecad and EGFR (i), or co-stained with phalloidin and antibodies
notype (either Ecad negative or F-actin positive) that fail to express
nalyzed by flow cytometry for cell surface expression of EGFR. (D)
or the EGFR inhibitor, AG1478 (1 μM). Afterward, whole cell lysates
vels of EGFR. (E) The outgrowth of NME and NME-LM cells grown
s quantified by bioluminescence. Data are the mean (±SE) of 3
ated P values. (F) NME and NME-LM cells were serum starved for 6
ns of EGF for 30 minutes. Whole cell lysates were analyzed for
for total EGFR (tEGFR). Erk1/2 served as a loading control. Data in
eriments yielding similar results.
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detectable in the TGF-β1 pretreated NME tumors (Figure 3A). In
contrast to our in vitro data fluorescence-activated cell sorting for this
ex vivo EGFR(-) population yielded a very mesenchymal cell population
(Figure 3A; inset) that failed to thrive when cultured alone.
Immunofluorescent staining verified the presence of a highly
mesenchymal population of cells that lacked expression of Ecad and
displayed a very filamentous actin cytoskeleton (Figure 3B). More
importantly, although resistant to puromycin, EGFR was undetectable
in this mesenchymal cell population (Figure 3B). Similar comparison of
cell surface EGFR levels between the parental NME cells and their
metastatic and isogenic NME-LM counterparts also displayed amarkedFigure 4. Expression of EGFR is diminished during the metastatic
progression of human BCs. (A) The human MCF10A progression
series consisting of normal (MCF10A), transformed (T1k), malignant
(Ca1h), and metastatic (Ca1a) cells were serum deprived and
stimulated with EGF for 30 minutes and subsequently analyzed for
EGFR phosphorylation (pEGFR) and total expression of EGFR and
Mig6. Actin served as a loading control. (B) HumanMDA-MB-231 BC
cellswere engrafted onto themammary fat pad of female nu/numice
and resulting metastases from the lymph node and lungs were
harvested and subcultured. These two independent cell lines and the
parental cells were stimulatedwith TGF-β1 for 48 hours and analyzed
for expression of EGFR and Mig6. Actin served as a loading control.
(C) ThemurineNMEprogression serieswas analyzedby immunoblot
for the expression EGFR and Mig6 under nonstimulated conditions
(−) and following a 48 hour treatment with TGF-β1 (5 ng/ml). Data in
A-C are representative of at least 3 independent experiments yielding
similar results.reduction in cell surface EGFR levels (Figure 3C). Analysis of total and
phosphorylated levels of EGFR similarly revealed a marked diminution
in the NME-LM cells as compared to their parental NME cells
(Figure 4D, F). Given that EGFR is recombinantly overexpressed in the
NME system we sought to identify possible mechanisms of negative
selection that could be altering the observed EGFR expression levels in
NME-LM cells. Consistent with a negative selection against high level
EGFR expression, prolonged stimulation of NME-LM cells with
exogenous EGF results in apoptosis (Figure 3D) and drastic inhibition
of outgrowth when cultured under 3D organotypic conditions
(Figure 3E). These findings contrast sharply with those obtained in
the parental NME cell line in which apoptosis and growth inhibition
results upon treatment with the EGFR inhibitor AG1478 (Figure 3D
and E). Furthermore, the maintenance of 3D growth of the NME-LM
cells in the presence of AG1478 (Figure 3E) is consistent with our
in vivo data (Figure 2), as well as with the clinical inability of
EGFR-targeted therapies to effectively treat metastatic BC [4].
To verify that diminution of EGFR is not an artifact of our
overexpression system, we assessed EGFR expression across the human
MCF-10A BC progression series. Consistent with the results of our
NME progression series, the fully metastatic MCF-Ca1a cells expressed
very little EGFR (Figure 4A). Consistent with our previous studies in
the NME cells, endogenous EGFR expression was not affected upon
in vitro TGF-β1 stimulation of the MDA-MB-231, but was markedly
lower in ex vivo cells that hadmetastasized from themammary fat pad to
axillary lymph nodes and lungs (Figure 4B). Expression of Mig6
mirrored that of EGFR and was similarly diminished in increasingly
metastatic BC cells (Figure 4, A and B). Consistent with the notion that
EGFR and Mig6 expression levels track together, the slight increase in
EGFR expression observed in the NME-LM2 cells as compared to the
NME-LM cells correlated with a corresponding increase in Mig6
(Figure 4C). Furthermore, Mig6 is maintained upon TGF-β treatment
of the NME-LM2 cells, which is contrast to their nonmetastatic
counterparts in which Mig6 is decreased during TGF-β-induced EMT
(Figure 4C). The precise mechanisms that lead to the paradoxical
function and diminution of EGFR following EMT and metastasis are
likely to be highly complex. Nevertheless, our data clearly indicate
that the processes of metastasis support the inherent resistance of BC
to EGFR-targeted therapies via a shift in EGFR signaling from pro-
to antitumorigenic.
There is a Direct Relationship Between EGFR and Mig6
Expression in Basal-Like Breast Cancer
To expand our findings beyond our in vitromodel systems we sought
to further examine the regulation of EGFR and Mig6 in clinical BC
samples. Therefore, we analyzed the TCGA BC dataset for the
expression relationship between EGFR andMig6 [24]. Consistent with
our findings in Figure 4, there was a significant direct correlation
between EGFR and Mig6 expression (Figure 5A). Next, we analyzed
the GEO data set GSE3744 in which patient BCs are classified as basal
like and non-basal like as characterized by microarray analysis [23].
Consistent with EGFR being a major defining factor of basal-like BC
[27] and there being a direct correlation between EGFR and Mig6,
Mig6 expression was significantly higher in this more aggressive subtype
(Figure 5B). Finally, we analyzed the cell line encyclopedia (CCLE) to
establish the ratio ofMig6 to EGFR across the 58 available BC cell lines
(Figure 5C). This analysis indicated that similar to the clinical datasets
there is a robust direct relationship betweenMig6 and EGFR expression
(Figure 5C). Two basal-like cell lines, the MDA-MB-231 (MDA-231)
Figure 5. Expression of Mig6 and EGFR are directly related and required at a balanced ratio for basal-like BC survival in response to EGF. (A)
Analysis of the TCGABCdata set comparingexpressionofMig6 versusEGFR. (B) Geodata setGSE3744wasanalyzed for expression levelsof
Mig6 between non basal-like and basal-like BCs. Data are theMig6 expression values for individual patient samples resulting in the indicated
means (±SE) andP value. (C) Expression levels of EGFR in relation toMig6 across 58 humanBCcell lines recorded in the CCLEdatabase. The
data points for MDA-MB-231 and MDA-MB-468 cells are noted. (D) MDA-MB-231 and MDA-MB-468 were treated with the indicated
concentrations of EGF for 48 hours and DNA synthesis was quantified by 3H Thymidine incorporation. Data are the mean (±SE) of at least 2
independent experiments carried out in triplicate where * indicates a P≤ .01. (E) MDA-MB-231 cells were stably constructed to overexpress
EGFR or YFP as a control. Phosphorylation of EGFR in response to EGF aswell total expression of EGFR andMig6were analyzed bywestern
blot. Actin served as a loading control. (F) Control (YFP) and EGFR overexpressing MDA-MB-231 cells were cultured under 3D growth
conditions in the presenceor absence of EGF (50 ng/ml) for 11 days and 3Doutgrowthwas quantified by bioluminescence.Data are themean
of three independent experiments conducted in triplicate resulting in the indicated P values.
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the second highest and lowest Mig6/EGFR expression ratio,
respectively. In contrast to the MDA-231 cells, EGF stimulation of
the MDA-468 cells is known to induce apoptosis [14]. Along these
lines, EGF stimulation results in a progressive decrease in [3H]
Thymidine incorporation in the MDA-468 cells, but not in the
MDA-231 cells (Figure 5D). In an attempt to manipulate the Mig6/
EGFR ratio in theMDA-231 cells we overexpressed EGFR (Figure 5E).
However, consistent with all of the correlative data above, recombinant
overexpression of EGFR in the MDA-231 cells lead to a concomitant
increase in Mig6 expression levels (Figure 5E). These data support our
conclusion that there is a direct relationship between expression levels of
EGFR and Mig6 in metastatic BC (Figure 5E). Finally, outgrowth of
the MDA-231 cells under 3D pulmonary organotypic conditions
confirmed an antitumorigenic effect of EGF in these metastatic BC
cells, a result that was significantly enhanced upon overexpression of
EGFR (Figure 5F).
Mig6 is Required for the Metastatic Outgrowth of MDA-MB-
231 Cells
Our findings in Figure 5 suggest that the 3D outgrowth inhibitory
effects of EGFR may be partially masked in MDA-231 cells upon
EGFR overexpression due to concomitant upregulation of Mig6(Figure 5E). To identify the role ofMig6 in empoweringmetastatic BCs
with the ability to subvert growth inhibitory EGFR signaling, we
utilized shRNAs to specifically deplete Mig6 in the MDA-231 cells
(Figure 6A). Consistent with our previous data in Figures 4 and 5,
depletion of Mig6 using two independent shRNAs led to a
corresponding decrease in EGFR levels, however receptor levels were
still readily detectable in these cells (Figure 6A). Depletion of Mig6
dramatically inhibited the 3D-outgrowth of MDA-231 cells indepen-
dent of addition of exogenous EGF (Figure 6B and C). Examination of
these 3D cultures revealed the appearance of several apoptotic bodies
(arrows, Figure 6B). This observation was verified by increased levels of
Caspase3/7 activity in Mig6-depleted MDA-231 cells as compared to
their control scrambled shRNA-expressing counterparts (Figure 6D).
Consistent with increased levels of apoptosis, we found that MDA-231
cells lacking Mig6 expression immediately failed to thrive within the
pulmonary microenvironment after being injected into the lateral tail
vein mice (Figure 6, E and F), thereby dramatically inhibiting the
formation of pulmonary tumors by Mig6-deficient MDA-231 cells as
compared to their Mig6 proficient counterparts (Figure 6, E–G).
Discussion
The current study delineates the evolution of EGFR function over the
metastatic progression of BC. Our previous studies demonstrate the
Figure 6. Mig6 depletion induces apoptosis and prevents pulmonary metastasis of MDA-MB-231 cells. (A) MDA-MB-231 cells stably
expressing a scrambled (sc) shRNA or three independent Mig6 targeted shRNAs were analyzed for Mig6 and EGFR expression by
immunoblot. Actin served as a loading control. (B and C) Luciferase expressing, Mig6-depleted MDA-MB-231 cells were grown under 3D
culture conditions and cellular outgrowth was quantified by bioluminescence. Photomicrographs in panel B are representative structures
formed by control (scram) and Mig6-depleted (shMig6) cells. Arrows indicate apoptotic cell morphologies. Data in panel C are the average
bioluminescent (±SE) values normalized to valuesmeasured immediately after plating (T0) from two independent experiments carried out in
triplicate. (D) The floating cell fraction of control and Mig6-depleted MDA-MB-231 cells were collected and assayed for Caspase 3/7 activity.
(E) Control (scram) and Mig6-depleted (shMig6) MDA-MB-231 cells were injected into the lateral tail vein of nu/nu mice. Longitudinal
bioluminescent images from the same mice are shown immediately following injection (T0) and at the indicated time points thereafter. (F)
Data are themean (±SE, n= 5mice per group) pulmonary bioluminescent values, normalized to the injected value (T0). (G) Representative ex
vivo lungs isolated from mice 49 days after injection with control (scram) or Mig6-depleted (shMig6) MDA-MB-231 cells.
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epithelial cells and the ability of EMT to drive EGFR-mediated
invasion and dissemination [1].However, our findings herein have goneon to establish a proapoptotic switch in EGFR function in the later
stages of metastatic outgrowth, a process that can be regulated by
corresponding expression of Mig6.
132 An EGFR Paradox in Metastatic Breast Cancer Wendt et al. Neoplasia Vol. 17, No. 1, 2015The notion that EGFR can play an anti-tumorigenic role in late-stage
BC is supported by our recent study in which we observed loss of EGFR
expression in metastatic outgrowth proficient D2.A1 BC cells as
compared to their invasive but systemically dormant D2.OR
counterparts [18]. We also previously demonstrated the progressive
loss of EGFR expression in the NME cells during in vitro recovery from
TGF-β-induced EMT [18]. This progressive down-regulation of EGFR
during oncogenic mesenchymal-epithelial transition (MET) is further
supported herein by our data utilizing the MCF-10A progression series
where EGFR expression is diminished inCa1a cells as compared to their
Ca1h counterparts. Indeed, separate studies demonstrate a MET
reaction characterizes the metastatic progression of these two cell lines
[28]. Along these lines, EGFR is undetectable in the highly metastatic
4T1model of BC (unpublished observation), a cell line we have recently
characterized to undergo EMT:MET reactions during tumor growth
and metastasis [2]. The importance of this bifurcated expression of
EGFR is born out by clinical data that indicate BCs expressing very high
or low levels of EGFR have similarly poorer outcomes as compared to
BCs expressing intermediate levels of EGFR [29]. Our findings herein
expand upon these primary tumor-derived data to suggest that even
high-level EGFR expression is diminished during formation of the
metastatic lesion. These data are consistent with clinical findings that have
demonstrated dowregulation of EGFR2 (Her2) in metastatic versus
primary tumors [30]. Whether this discordance in receptor expression
results due active downregulation of EGFR expression or selection of a
preexisting EGFRlow subpopulation remains to be established.
In addition to depletion of EGFR, our data in Figures 4 and 5 suggest
that metastatic BCs can also neutralize EGFR-driven apoptosis via
Mig6. This exciting finding is contrasted sharply by the widely assumed
notion that Mig6 functions solely as a tumor suppressor, a supposition
that holds to the idea that EGFR signaling universally functions in an
oncogenic manner [10,31]. However, it should be noted that several
recent studies have established the ability of EGFR to induce apoptosis
in BCs [15–17,32], while others have established the ability of Mig6 to
protect human BC cells from apoptosis [33]. Indeed, genetic
inactivation of Mig6 results in pulmonary endothelial cell apoptosis
[13]. Likewise, a recent study demonstrated that EGF-induced
apoptosis in MDA-468 cells, which scored the lowest Mig6:EGFR
ratio in our 58 cell line analysis, occurs upon EGFR internalization [17].
Therefore, it is tempting to speculate that unbalanced expression levels
of Mig6 with relation to EGFR leads to unabated activation of
internalized EGFR, initiating a pro-apoptotic event. Why this does not
occur in normal and premalignant cells in which overexpression of
EGFR is strictly protumorigenic is a subject currently under
investigation in our laboratory.
In summary, our study has delineated a paradoxical shift in which the
potent growth promoting properties of EGFR are converted to
antitumorigenic mechanisms during the later stages of metastatic
progression. Furthermore, we show that the antitumorigenic properties
of EGFR in metastatic BC cells are held at bay by the EGFR inhibitory
molecule Mig6. This EGFR paradox presents a plausible explanation
for the inherent resistance ofmetastatic BC to EGFR-targeted therapies.
Understanding the evolution in EGFR and other RTK signaling across
the metastatic cascade will be essential for the proper application of their
respective targeted therapies for the treatment of metastatic BC.
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